Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors

NCT04742959 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT04742959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 14, 2021
Completion date
February 20, 2024
Enrollment
203 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, cholangiocarcinoma, gallbladder cancer, gastric cancer, her2-negative breast cancer, prostate cancer, sarcoma, small-cell lung cancer, thyroid cancer, triple negative breast cancer